HNC364(HNC364) - 在研适应症：帕金森病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病内分泌与代谢疾病

在研适应症

帕金森病

非在研适应症-

原研机构

广州市恒诺康医药科技有限公司

在研机构

广州市恒诺康医药科技有限公司

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床申请

特殊审评-

登录后查看时间轴

关联

2

项与 HNC364 相关的临床试验

NCT06798519

/ Not yet recruiting临床1期

A Relative Bioavailability Study of HNC364 Following Intramuscular Injections Vs. AZILECT® (Rasagiline Tablet) Following Oral Administration At the Steady-State in Healthy Adult Subjects

HNC364 is a new pro-drug of rasagiline as a long-acting injection for deep IM deltoid injection, for the treatment of Parkinson"s disease (PD). As a pro-drug of rasagiline, HNC364 will readily and completely convert to rasagiline after the IM administration.
This is a non-randomized, open-label, Phase 1 study to evaluate the relative bioavailability of HNC364 injectable suspension relative to AZILECT® (rasagiline tablets), to assess the safety and tolerability of multiple IM dose HNC364 injectable suspension dose administration in healthy adult subjects.

开始日期2025-05-01

申办/合作机构

广州市恒诺康医药科技有限公司

NCT05523570

/ Completed临床1期

Phase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable Suspension

This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.

开始日期2022-08-22

申办/合作机构-

100 项与 HNC364 相关的临床结果

登录后查看更多信息

100 项与 HNC364 相关的转化医学

登录后查看更多信息

100 项与 HNC364 相关的专利（医药）

登录后查看更多信息

100 项与 HNC364 相关的药物交易

登录后查看更多信息